Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Launched by HUASHAN HOSPITAL · Nov 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying new ways to manage blood sugar levels in patients who have both liver cirrhosis and diabetes. Poorly controlled blood sugar can worsen health outcomes in these patients, so finding a better treatment strategy is very important. The trial is testing a combination of medications, including metformin and Ryzodeg, to see if they can help control blood sugar levels without causing dangerous drops in blood sugar (hypoglycemia) or other serious side effects. Researchers will compare this new treatment plan with the traditional approach that relies heavily on insulin.

To participate in the trial, individuals must be between 18 and 70 years old, have liver cirrhosis, and have high blood sugar levels. However, those with certain health issues, such as severe heart problems or advanced liver cancer, will not be eligible. Participants can expect to receive careful monitoring throughout the study to ensure their safety and track how well the treatment works. This trial aims to provide valuable information that could lead to improved guidelines for treating diabetes in patients with liver cirrhosis, ultimately helping to enhance their overall health and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Liver cirrhosis
• • Age 18-70 years
• • Patients with elevated blood sugar who meet the diabetes standard or have been treated with hypoglycemic drugs
• • random finger or venous serum blood glucose more than 14 mmol/L
• Exclusion Criteria:
• • Those unwilling to participate or unable to cooperate;
• • Child-pugh score is greater than 12;
• • Glomerular filtration rate\<60ml/min/1.73m2;
• • Patients with cardiac insufficiency;
• • Patients with asymptomatic hypoglycemia;
• • Pregnant patients were excluded;
• • Patients with advanced liver cancer;
• • Blood pressure is less than 90/60mmHg;
• • Chronic liver disease plus acute or subacute liver failure;
• • Patients with drug induced blood glucose disorder, such as glucocorticoids, contraceptives, etc;
• • fingertip oxygen saturation less than 95% without oxygen inhalation;
• • Autoimmune liver cirrhosis is currently taking hormone.
• • Type 1 diabetes.
• • Pancreatogenic diabetes, such as primary hemochromatosis, hepatolenticular degeneration, alcoholic pancreatitis, autoimmune diseases involving the pancreas, etc.

Trial Officials